Maylene Peralta, MD
Endocrinology, Diabetes & Metabolism · Redding, CANPI 1033183553
Payments from drug & device makers
Across 11 payments — averaging $142.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Tandem Diabetes Care, Inc.$105
- Insulet Corporation$92
- Ascendis Pharma Endocrinology Inc$57
- Amgen$27
What the payments were for
- Speaking & faculty fees$1,25080%
- Food & beverage$30419%
- Education$141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 3 | $1,287 |
| Tandem Diabetes Care, Inc. | 1 | $105 |
| Insulet Corporation | 3 | $92 |
| Ascendis Pharma Endocrinology Inc | 2 | $57 |
| Amgen | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,568 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 465 | $541,520 |
| MounjaroTirzepatide | 394 | $451,111 |
| Tresiba Flextouch U-200Insulin Degludec | 427 | $344,050 |
| JardianceEmpagliflozin | 225 | $225,551 |
| FarxigaDapagliflozin Propanediol | 184 | $166,486 |
| TrulicityDulaglutide | 135 | $136,195 |
| RybelsusSemaglutide | 72 | $89,612 |
| Tolvaptan | 13 | $60,905 |
| Tresiba Flextouch U-100Insulin Degludec | 93 | $55,686 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $51,625 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 42 | $44,969 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $40,843 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $36,079 |
| TradjentaLinagliptin | 35 | $31,687 |
| Repatha SyringeEvolocumab | 39 | $30,523 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Redding
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.